A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.
Completed
Allergan
Phase 2
2005-11-01
The purpose of this study is to evaluate the safety and effectiveness of ACZONE™ gel compared
to placebo (inactive substance), MetroGel® and a combination of ACZONE™ gel and MetroGel® for
the treatment of rosacea.
ACZONE™ gel, 5% is a topical (applied to the skin) medication that is approved by the United
States Food and Drug Administration (FDA) for the treatment of acne vulgaris in people 12
years and older. The use of ACZONE™ for the treatment of rosacea is investigational. An
investigational use is one that is not approved by the FDA.
Subjects will apply the study treatment for 12 weeks. Efficacy assessments will be performed
at baseline and Weeks 2, 4, 8, and 12. Laboratory assessments will be conducted at baseline
and Week, 2, 4 and 12.
Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application
Completed
Galderma Laboratories, L.P.
Phase 4
2006-08-01
This eight-hour kinetic regression clinical study was conducted to assess the ability of
MetroGel® 1% to deliver moisture to facial skin after a single application.
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
Completed
University of California, San Francisco
Phase 2
2008-04-01
This is a phase IIa clinical trial in women with bacterial vaginosis. This study will
determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy
(metronidazole) is effective in colonizing the vagina with the lactobacillus bacteria found
in normal vaginal flora.
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
Completed
Osel, Inc.
Phase 2
2008-04-01
This is a phase IIa clinical trial in women with bacterial vaginosis. This study will
determine whether treatment with vaginal lactobacillus in combination with antibiotic therapy
(metronidazole) is effective in colonizing the vagina with the lactobacillus bacteria found
in normal vaginal flora.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
